JNJ-55308942

From WikiProjectMed
Jump to navigation Jump to search
JNJ-55308942
Legal status
Legal status
  • Investigational New Drug
Identifiers
  • (S)-(3-fluoro-2-(trifluoromethyl)pyridin-4-yl)(1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone
CAS Number
PubChem CID
Chemical and physical data
FormulaC17H12F5N7O
Molar mass425.323 g·mol−1
3D model (JSmol)
  • C[C@H]1CC2=C(CN1C(=O)C3=C(C(=NC=C3)C(F)(F)F)F)N=NN2C4=NC=C(C=N4)F
  • InChI=1S/C17H12F5N7O/c1-8-4-12-11(26-27-29(12)16-24-5-9(18)6-25-16)7-28(8)15(30)10-2-3-23-14(13(10)19)17(20,21)22/h2-3,5-6,8H,4,7H2,1H3/t8-/m0/s1
  • Key:LMDWZBQISRTEBH-QMMMGPOBSA-N

JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release.[1][2][3] It is developed by Janssen Pharmaceuticals for bipolar depression.[4]

See also

References

  1. ^ Bhattacharya, Anindya; Lord, Brian; Grigoleit, Jan-Sebastian; He, Yingbo; Fraser, Ian; Campbell, Shannon N.; Taylor, Natalie; Aluisio, Leah; O’Connor, Jason C.; Papp, Mariusz; Chrovian, Christa; Carruthers, Nicholas; Lovenberg, Timothy W.; Letavic, Michael A. (December 2018). "Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia". Neuropsychopharmacology. 43 (13): 2586–2596. doi:10.1038/s41386-018-0141-6. ISSN 0893-133X. PMC 6224414. PMID 30026598.
  2. ^ Bhattacharya, Anindya; Ceusters, Marc (January 2020). "Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders". Neuropsychopharmacology. 45 (1): 234–235. doi:10.1038/s41386-019-0502-9. ISSN 0893-133X. PMC 6879571. PMID 31477815.
  3. ^ Kolb, Hartmuth C.; Barret, Olivier; Bhattacharya, Anindya; Chen, Gang; Constantinescu, Cristian; Huang, Chaofeng; Letavic, Michael; Tamagnan, Gilles; Xia, Chunfang A.; Zhang, Wei; Szardenings, Anna Katrin (August 2019). "Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18 F-JNJ-64413739, a PET Radioligand for P2X7 Receptors". Journal of Nuclear Medicine. 60 (8): 1154–1159. doi:10.2967/jnumed.118.212696. ISSN 0161-5505. PMID 30733317. S2CID 73454130.
  4. ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 27 November 2023.
Retrieved from "https://mdwiki.org/wiki/JNJ-55308942"